BioPorto has entered into a distribution agreement with Siemens Healthcare will deliver an NGAL test adapted for Siemens Healthcare's BN II and BN ProSpec Systems. The agreement is exclusive with regard to those instruments and has a worldwide scope. Siemens Healthcare's BN Systems are controlled systems that are designed for validated applications. Subsequent to completion of the adaption of the NGAL test to those instruments, the agreement includes a period in which Siemens Healthcare and BioPorto will collaborate to bring the adapted test to market.

Commercial sales will commence after completion of the adaption. The agreement has significant strategic importance to the availability of NGAL tests and the awareness of NGAL as a diagnostic marker. BioPorto expects to see an economic effect of this agreement in the second half of 2016.